bpc-157 spinal cord injury models The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity Stable gastric pentadecapeptide BPC 157

10.3174/ajnr.A1579 121

A 2015 study by Huang and colleagues in Drug Design, Development and Therapy used a rat alkali-burn model (n=10 per group) and HUVECs treated with BPC-157 at 200800 ng/mL, reporting accelerated wound closure with enhanced granulation tissue, reepithelialization, and dermal remodeling by day 18, alongside increased endothelial migration and vascular tube formation in vitro via ERK1/2 phosphorylation though the abstract does not report numeric % wound closure or p-values

C

This maintenance phase begins only after the initial deficiency has been corrected and the patients blood markers have stabilized within the normal range